The people who prepared in advance described those weeks as manageable but unpleasant. The people who did not prepare described them as nearly unbearable. Same medication, wildly different experiences based purely on preparation
Weight loss is preserved across age groups, with no consistent evidence of harmful unintended reductions
Anthracycline radical formation by NADH dehydrogenase
Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up
This week, lets look at the enduring questions surrounding GLP-1 agonist drugs
